Asif Ali Biography and Net Worth

Mr. Ali joined as Chief Financial Officer (CFO) in April 2022. Mr. Ali previously served as Chief Accounting Officer at Theravance Biopharma, overseeing various departments including FP&A, taxation, accounting and financial reporting, strategic sourcing, and finance operations. Among other notable achievements while at Theravance, he was part of the team that successfully raised $130 million in equity financing in February 2020, and a further $115 million in June 2021. Before that, he was Vice President and Corporate Controller at Depomed, where he supported five product launches and four successful product acquisitions. Mr. Ali is a fellow of the Institute of Chartered Accountants in England & Wales, a qualification that he obtained in conjunction with studying accounting at the University of North London, UK, the US equivalent of a B.S. in Business Administration with a concentration in accounting.

What is Asif Ali's net worth?: The estimated net worth of Asif Ali is at least $5.87 million as of April 20th, 2026. Mr. Ali owns 59,003 shares of Protagonist Therapeutics stock worth more than $5,871,979 as of May 5th. This net worth evaluation does not reflect any other investments that Mr. Ali may own. Learn More about Asif Ali's net worth.
How do I contact Asif Ali?: The corporate mailing address for Mr. Ali and other Protagonist Therapeutics executives is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. Protagonist Therapeutics can also be reached via phone at (510) 474-0170 and via email at [email protected]. Learn More on Asif Ali's contact information.
Has Asif Ali been buying or selling shares of Protagonist Therapeutics?: During the last ninety days, Asif Ali has sold $184,572.50 in shares of Protagonist Therapeutics stock. Most recently, Asif Ali sold 1,750 shares of the business's stock in a transaction on Monday, April 20th. The shares were sold at an average price of $105.47, for a transaction totalling $184,572.50. Following the completion of the sale, the chief financial officer now directly owns 59,003 shares of the company's stock, valued at $6,223,046.41. Learn More on Asif Ali's trading history.
Who are Protagonist Therapeutics' active insiders?: Protagonist Therapeutics' insider roster includes Asif Ali (EVP, CFO), Suneel Gupta (Chief Development Officer), David Liu (Insider), Arturo Molina (Chief Medical Officer), Dinsesh Patel (CEO), Harold Selick (Director), William Waddill (Director), and Lewis Williams (Director). Learn More on Protagonist Therapeutics' active insiders.
Are insiders buying or selling shares of Protagonist Therapeutics?: In the last year, insiders at the sold shares 25 times. They sold a total of 416,241 shares worth more than $34,766,143.07. The most recent insider tranaction occured on April, 20th when CFO Asif Ali sold 1,750 shares worth more than $184,572.50. Insiders at Protagonist Therapeutics own 4.9% of the company. Learn More about insider trades at Protagonist Therapeutics.
Information on this page was last updated on 4/20/2026.

Asif Ali Insider Trading History at Protagonist Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/20/2026	Sell	1,750	$105.47	$184,572.50	59,003
3/26/2026	Sell	24,765	$104.24	$2,581,503.60	60,753
1/27/2026	Sell	46,203	$83.13	$3,840,855.39	60,320
1/20/2026	Sell	8,588	$82.48	$708,338.24	78,077
4/22/2025	Sell	1,756	$46.00	$80,776.00	61,065
3/12/2025	Sell	24,903	$58.73	$1,462,553.19	62,821
9/11/2024	Sell	14,203	$44.49	$631,891.47	34,960
4/18/2024	Sell	1,234	$25.11	$30,985.74	37,163
3/1/2024	Sell	14,248	$32.24	$459,355.52	38,397

Asif Ali Buying and Selling Activity at Protagonist Therapeutics

Protagonist Therapeutics Company Overview

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Today's Range

Now: $99.52

$98.00

$101.08

50 Day Range

MA: $98.50

$82.76

$105.98

2 Week Range

Now: $99.52

$41.28

$107.84

Volume

457,421 shs

Average Volume

680,716 shs

Market Capitalization

$6.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89